DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)
DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)
DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
42<br />
Your osteoporosis patients now have<br />
2 fully funded treatment options 1 *<br />
Daily or weekly oral treatment<br />
OR<br />
Aclasta<br />
Once-yearly<br />
infusion<br />
Which would you choose?<br />
Now<br />
Funded 1 *<br />
For more information visit www.aclasta.co.nz<br />
or call 0800 1 ACLASTA (0800 122 527)<br />
*Aclasta is fully funded for patients who meet specified criteria. Funding does not include the cost of infusion.<br />
References: 1. Pharmaceutical Schedule. Sept <strong>2010</strong>. 2. Aclasta Data Sheet.<br />
Aclasta ® is a Prescription Medicine, fully funded under Special Authority criteria for any patient who has had a prior Special Authority for alendronate a T score -3.0<br />
a T score -2.5 with an osteoporotic fracture a history of two osteoporotic fractures a history of one osteoporotic fracture with x-ray confirmation in frail elderly<br />
unable to access DXA scan a 10 year risk of hip fracture 3% calculated using a risk assessment algorithm (FRAX or GARVAN) receiving glucocorticosteroid therapy (<br />
5mg/day prednisone equivalent) for at least 3 months and either a T score of -1.5 or one osteoporotic fracture demonstrated radiologically. Note: Special Authorities are not<br />
interchangeable and the funding does not include the cost of infusion. Aclasta ® (zoledronic acid) 5mg/100mL infusion. Aclasta is a Prescription Medicine for the treatment of<br />
various causes of osteoporosis to prevent hip, vertebral and non-vertebral fractures. It is also indicated for Paget’s disease. Contraindications are hypocalcaemia, pregnancy and<br />
lactation. Precautions: Aclasta is not recommended in patients with renal impairment (creatinine clearance
Change language